Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Modified Apixaban in Japanese Patients with Cancer-Associated Venous Thromboembolism
jRCTs051220095Phase 2Recruiting
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apixaban in venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT). Primary endpoint: Primary composite bleeding outcome. Started Sep 2022; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on jRCTs051220095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220095.